Governor Josh Shapiro partners with CHOP to prevent Trump administration from accessing transgender youth medical records.
In an escalating legal dispute, Pennsylvania Governor Josh Shapiro has formally entered the fray involving the Children’s Hospital of Philadelphia (CHOP) and the Trump administration, regarding a federal subpoena that demands private medical records of transgender minors. This development comes amid ongoing national debates surrounding transgender healthcare and the rights of medical practitioners.
In a recent court filing, Shapiro contended that the regulation of medical practices falls under state jurisdiction, asserting that the Department of Justice (DOJ) is attempting to infringe upon this authority. Shapiro’s position emphasizes the critical importance of maintaining the integrity of doctor-patient relationships and preserving public trust in healthcare providers. He argues that allowing federal agencies to access sensitive health information could severely undermine these relationships, particularly for a vulnerable demographic.
The amicus curiae brief, a legal document that enables third parties with a vested interest in a case to present their perspectives, was filed Tuesday in a federal court in Philadelphia. This brief was submitted alongside the attorneys general of 14 additional states, including New Jersey, Delaware, and the District of Columbia. It reflects a growing concern among state officials regarding the balance of power between federal and state authorities in healthcare regulation.
The DOJ did not respond to requests for comment on this matter. The court has designated a deadline of November 4 for the DOJ to reply to the amicus brief, indicating the legal team’s diligence in addressing the emerging complexities of the case.
Earlier this year, the DOJ issued broad subpoenas not only to CHOP but also to at least 19 other hospitals across the country. These subpoenas are part of an inquiry into how healthcare providers administer gender-affirming care to minors, with federal officials critiquing these treatments as potentially harmful and mischaracterizing them as forms of “chemical mutilation.” This critical stance has sparked intense legal challenges in courts nationwide, with ongoing cases awaiting resolution in Pennsylvania and beyond.
U.S. District Court Judge Mark A. Kearney is currently evaluating a motion from CHOP to restrict the scope of the subpoena, citing patient privacy concerns. Notably, CHOP operates one of the premier clinics in the United States dedicated to providing comprehensive medical and mental health services for transgender and gender-nonbinary youth. Since its inception in 2014, the Gender and Sexuality Development Program at CHOP has seen a significant influx of families seeking specialized care.
The DOJ’s inquiry aims to scrutinize the prescription practices involving puberty blockers and hormones, specifically focusing on their off-label use—an accepted medical practice where approved medications are prescribed for conditions other than those expressly authorized by the U.S. Food and Drug Administration (FDA). Gender-affirming healthcare is supported by leading medical organizations, recognizing the high rates of psychological distress among youth experiencing gender dysphoria.
Shapiro and the coalition of attorneys general argue that upholding the subpoena would not only challenge states’ regulatory authority but also specifically target a form of medical care that is crucial for a particularly at-risk group, despite the absence of any federal law explicitly opposing such treatments. This legal battle continues to unfold, with implications for medical practices and the care of transgender individuals across the United States.
As this case progresses, it underscores significant questions regarding the intersection of healthcare, law, and human rights in the ongoing national discourse surrounding transgender issues. Media News Source.
